The intervening years have both sped and crawled by, too busy at times to take stock of all that has changed, too plodding to ...

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...

As a result, Moderna Inc. (NASDAQ:MRNA) was removed from the index. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro.

In September, Moderna unveiled key updates at its annual R&D Day, spotlighting its mRNA-based pipeline and revised financial plans. The company has witnessed a decline in its only approved ...

The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines. One of the ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Pharmaceutical and biotech stocks may find it tough to outperform the market in the ...

Infants are among the most vulnerable when it comes to RSV—but there's still no vaccination for them. A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive ...

In the US, citizens can pick between vaccines manufactures by Moderna, Pfizer and Novavax. According to CDC data, in about one in every 200,000 cases, a person develops an allergic reaction ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and Prevention (CDC) and Moderna have teamed up to design an mRNA vaccine ...

The early winners won big — especially the WFH plays like Zoom and Peloton, and, of course, vaccine makers like Pfizer and Moderna. All of these stocks have all had a rocky path back to ...

Aritzia (TSE:ATZ – Get Free Report) was downgraded by equities research analysts at Raymond James from an “outperform” rating ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...